Effect of Telmisartan on Ambulatory Blood Pressure Monitoring, Plasma Brain Natriuretic Peptide, and Oxidative Status of Serum Albumin in Hemodialysis Patients

Abstract

The effect of telmisartan on ambulatory blood pressure, plasma neurohormonal parameters, and oxidation of serum albumin has not been investigated in hemodialysis (HD) patients. Thirteen hypertensive HD patients were treated with 40 mg telmisartan once daily, and 24-h ambulatory blood pressure monitoring was performed after 0, 4, and 8 weeks of treatment. Plasma renin activity, plasma aldosterone concentration (PAC), brain natriuretic peptide (BNP) level, and serum oxidized albumin level were determined at the same time points. Serum telmisartan concentration was also measured at 4 and 8 weeks. Telmisartan significantly reduced systolic blood pressure and diastolic blood pressure (both awake and sleeping) after 4 weeks, and these pressures showed a further significant decrease after 8 weeks. Plasma levels of aldosterone, BNP, and serum oxidized albumin were markedly decreased after 4 weeks and these lower levels were maintained at 8 weeks. The trough serum telmisartan concentration was not significantly different at 8 weeks compared with 4 weeks. Throughout the treatment period, there were no significant adverse effects. Telmisartan effectively lowers blood pressure and reduces PAC, BNP, and oxidative stress and is safe and well-tolerated by HD patients. A long-term study in a large population is required to determine the influence of telmisartan therapy on cardiovascular mortality and morbidity in HD patients.

References

  1. 1

    Locatelli F, Marcelli D, Conte F, et al: Cardiovascular disease in chronic renal failure: the challenge continues. Nephrol Dial Transplant 2000; 15 ( Suppl): S69–S80.

    Article  Google Scholar 

  2. 2

    van den Hoogen PCW, Feskens EJM, Nagelkerke NJD, Menotti A, Nissinen A, Kromhout D : The relation between blood pressure and mortality due to coronary heart disease among men in different parts of the world. N Engl J Med 2000; 342: 1–8.

    CAS  PubMed  Article  Google Scholar 

  3. 3

    Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW : Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141–1148.

    CAS  Article  Google Scholar 

  4. 4

    Ruiz-Ortega M, Lorenzo O, Ruperez M, Konig S, Wittig B, Egido J : Angiotensin II activates nuclear transcription factor κB through AT1 and AT2 in vascular smooth muscle cells: molecular mechanisms. Circ Res 2000; 86: 1266–1272.

    CAS  PubMed  Article  Google Scholar 

  5. 5

    Tschudi MR, Mesaros S, Luscher TF, Malinski T : Direct in situ measurement of nitric oxide in mesenteric resistance arteries: increased decomposition by superoxide in hypertension. Hypertension 1996; 27: 32–35.

    CAS  PubMed  Article  Google Scholar 

  6. 6

    Weiss D, Kools JJ, Taylor WR : Angiotensin II-induced hypertension accelerates the development of atherosclerosis in ApoE-deficient mice. Circulation 2001; 103: 448–454.

    CAS  PubMed  Article  Google Scholar 

  7. 7

    Koh KK, Ahn JY, Han SH, et al: Pleiotropic effects of angiotensin II receptor blocker in hypertensive patients. J Am Coll Cardiol 2003; 42: 905–910.

    CAS  PubMed  Article  Google Scholar 

  8. 8

    Shibasaki Y, Masaki H, Nishiue T, Nishikawa M, Matsubara H, Iwasaka T : Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease. Nephron 2002; 90: 256–261.

    CAS  PubMed  Article  Google Scholar 

  9. 9

    Fishman S, Rapoport MJ, Weissgarten J, et al: The effect of losartan on insulin resistance and beta cell function in chronic hemodialysis patients. Ren Fail 2001; 23: 685–692.

    CAS  PubMed  Article  Google Scholar 

  10. 10

    Martina B, Dieterle T, Sigle JP, Surber C, Battegay E : Effects of telmisartan and losartan on left ventricular mass in mild-to-moderate hypertension. A randomized, double-blind trial. Cardiology 2003; 99: 169–170.

    PubMed  Article  Google Scholar 

  11. 11

    Lacourcière Y, Lenis J, Orchard R, et al: A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit 1998; 3: 295–302.

    PubMed  Google Scholar 

  12. 12

    Neutel JM, Frishman WH, Oparil S, Papademitriou V, Guthrie G : Comparison of telmisartan with lisinopril in patients with mild-to-moderate hypertension. Am J Ther 1999; 6: 161–166.

    CAS  PubMed  Article  Google Scholar 

  13. 13

    Karlberg BE, Lins LE, Hermansson K, TEES Study Group : Efficacy and safety of telmisartan, a selective AT1 receptor antagonist, compared with enalapril in elderly patients with primary hypertension. J Hypertens 1999; 17: 293–302.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  14. 14

    Sharpe M, Jarvis B, Goa KL : Telmisartan: a review of its use in hypertension. Drugs 2001; 61: 1501–1529.

    CAS  PubMed  Article  Google Scholar 

  15. 15

    Neutel JM, Klein C, Meinicke TW, Schumacher H : Long-term efficacy and tolerability of telmisartan as monotherapy and in combination with other antihypertensive medications. Blood Press 2002; 11: 302–309.

    CAS  PubMed  Article  Google Scholar 

  16. 16

    Freytag F, Holwerda NJ, Karlberg BE, Meinicke TW, Schumacher H : Long-term exposure to telmisartan as monotherapy or combination therapy: efficacy and safety. Blood Press 2002; 11: 173–181.

    CAS  PubMed  Article  Google Scholar 

  17. 17

    Mallion J, Siche J, Lacourcière Y, the Telmisartan Blood Pressure Monitoring Group : ABPM comparison of the antihypertensive profiles of the selective angiotensin II receptor antagonists telmisartan and losartan in patients with mild-to-moderate hypertension. J Hum Hypertens 1999; 13: 657–664.

    CAS  PubMed  PubMed Central  Article  Google Scholar 

  18. 18

    Anraku M, Kitamura K, Shinohara A, et al: Intravenous iron administration induces oxidation of serum albumin in hemodialysis patients. Kidney Int 2005; 66: 841–848.

    Article  Google Scholar 

  19. 19

    Kario K, Pickering TG, Umeda Y, et al: Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401–1406.

    PubMed  Article  Google Scholar 

  20. 20

    Tatami S, Sarashina A, Yamamura N, Igarashi T, Tanigawara Y : Population pharmacokinetics of an angiotensin II receptor antagonist, telmisartan, in healthy volunteers and hypertensive patients. Drug Metab Pharmacokinet 2003; 18: 203–211.

    CAS  PubMed  Article  Google Scholar 

  21. 21

    Amerena J, Pappas S, Ouellet JP, Williams L, O'Shaughnessy D : ABPM comparison of the anti-hypertensive profiles of telmisartan and enalapril in patients with mild-to-moderate essential hypertension. J Int Med Res 2002; 30: 543–552.

    CAS  PubMed  Article  Google Scholar 

  22. 22

    Gil-Extremera B, Ma PT, Yulde J, Kalnins U, Harkin N, Williams L : The adjunctive effect of telmisartan in patients with hypertension uncontrolled on current antihypertensive therapy. Int J Clin Pract 2003; 57: 861–866.

    CAS  PubMed  Google Scholar 

  23. 23

    Neutel JM : Ambulatory blood pressure monitoring to assess the comparative efficacy and duration of action of a novel new angiotensin II receptor blocker—telmisartan. Blood Press 2001; 10 ( Suppl 1): 27–32.

    Article  Google Scholar 

  24. 24

    Neutel JM, Kolloch RE, Plouin PF, Meinicke TW, Schumacher H, for the OTELLOH Study Group : Telmisartan vs losartan plus hydrochlorothiazide in the treatment of mild-to-moderate essential hypertension—a randomised ABPM study. J Hum Hypertens 2003; 17: 569–575.

    CAS  PubMed  Article  Google Scholar 

  25. 25

    Lacourcière Y, Lenis J, Orchard R, et al: A comparison of the efficacies and duration of action of the angiotensin II receptor blockers telmisartan and amlodipine. Blood Press Monit 1998; 3: 295–302.

    PubMed  Google Scholar 

  26. 26

    Neutel JM, Littlejohn TW, Chrysant SG, Singh A, for the Telmisartan Study Group : Telmisartan/hydrochlorothiazide in comparison with losartan/hydrochlorothiazide in managing patients with mild-to-moderate hypertension. Hypertens Res 2005; 28: 555–563.

    CAS  PubMed  Article  Google Scholar 

  27. 27

    Uzu T, Kimura G : Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. Circulation 1999; 100: 1635–1638.

    CAS  PubMed  Article  Google Scholar 

  28. 28

    Goto N, Uchida K, Morozumi K, et al: Circadian blood pressure rhythm is disturbed by nephrectomy. Hypertens Res 2005; 28: 301–306.

    PubMed  Article  Google Scholar 

  29. 29

    Yasue H, Yoshimura M, Sumida H, et al: Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation 1994; 90: 195–203.

    CAS  PubMed  Article  Google Scholar 

  30. 30

    Morita E, Yasue H, Yoshimura M, et al: Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction. Circulation 1993; 88: 82–91.

    CAS  PubMed  Article  Google Scholar 

  31. 31

    Nagaya N, Nishikimi T, Goto Y, et al: Plasma brain natriuretic peptide is a biochemical marker for the prediction of progressive ventricular remodeling after acute myocardial infarction. Am Heart J 1998; 135: 21–28.

    CAS  PubMed  Article  Google Scholar 

  32. 32

    Nishikimi T, Yoshihara F, Morimoto A, et al: Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996; 28: 22–30.

    CAS  PubMed  Article  Google Scholar 

  33. 33

    Anand IS, Fisher LD, Chiang YT, et al: Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003; 107: 1278–1283.

    CAS  PubMed  Article  Google Scholar 

  34. 34

    Latini R, Masson S, Anand I, et al: Effects of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure: the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2002; 106: 2454–2458.

    CAS  PubMed  Article  Google Scholar 

  35. 35

    Zoccali C, Mallamaci F, Benedetto FA, et al: Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol 2001; 12: 1508–1515.

    CAS  PubMed  Google Scholar 

  36. 36

    Descamps-Latscha B, Witko-Sarsat V : Importance of oxidatively modified proteins in chronic renal failure. Kidney Int Suppl 2001; 78: S108–S113.

    CAS  PubMed  Article  Google Scholar 

  37. 37

    Daschner M, Lenhartz H, Botticher D, et al: Influence of dialysis on plasma lipid peroxidation products and antioxidant levels. Kidney Int 1996; 50: 1268–1272.

    CAS  PubMed  Article  Google Scholar 

  38. 38

    Witko-Sarsat V, Gausson V, Nguyen AT, et al: AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney Int 2003; 64: 82–91.

    CAS  PubMed  Article  Google Scholar 

  39. 39

    Witko-Sarsat V, Gausson V, Descamps-Latscha B : Are advanced oxidation protein products potential uremic toxins? Kidney Int Suppl 2003; 84: S11–S14.

    CAS  Article  Google Scholar 

  40. 40

    Witko-Sarsat V, Friedlander M, Capeillere-Blandin C, et al: Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney Int 1996; 49: 1304–1313.

    CAS  PubMed  Article  Google Scholar 

  41. 41

    Odetti P, Garibaldi S, Gurreri G, Aragno I, Dapino D : Protein oxidation in hemodialysis and kidney transplantation. Metabolism 1996; 45: 1319–1322.

    CAS  PubMed  Article  Google Scholar 

  42. 42

    Himmelfarb J, McMonagle E : Albumin is the major plasma protein target of oxidant stress in uremia. Kidney Int 2001; 60: 358–363.

    CAS  PubMed  Article  Google Scholar 

  43. 43

    Sogami M, Nagoka S, Era S, Honda M, Noguchi K : Resolution of human mercapt- and nonmercaptalbumin by high-performance liquid chromatography. Int J Pept Protein Res 1984; 24: 96–103.

    CAS  PubMed  Article  Google Scholar 

  44. 44

    Hayakawa A, Kuwata K, Era S, et al: Alteration of redox state of human serum albumin in patients under anesthesia and invasive surgery. J Chromatogr B Biomed Sci Appl 1997; 698: 27–33.

    CAS  PubMed  Article  Google Scholar 

  45. 45

    Sogami M, Era S, Nagaoka S, et al: High-performance liquid chromatographic studies on non-mercapt in equilibrium with mercapt conversion of human serum albumin. J Chromatogr 1985; 332: 19–27.

    CAS  PubMed  Article  Google Scholar 

  46. 46

    Suzuki E, Yasuda K, Takeda N, et al: Increased oxidized form of human serum albumin in patients with diabetes mellitus. Diabetes Res Clin Pract 1992; 18: 153–158.

    CAS  PubMed  Article  Google Scholar 

  47. 47

    Soejima A, Kaneda F, Manno S, et al: Useful markers for detecting decreased serum antioxidant activity in hemodialysis patients. Am J Kidney Dis 2002; 39: 1040–1046.

    CAS  PubMed  Article  Google Scholar 

  48. 48

    Rajagopalan S, Duquaine D, King S, Pitt B, Patel P : Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 2002; 105: 2212–2216.

    CAS  PubMed  Article  Google Scholar 

  49. 49

    Takai S, Kirimura K, Jin D, et al: Significance of angiotensin II receptor blocker lipophilicities and their protective effect against vascular remodeling. Hypertens Res 2005; 28: 593–600.

    CAS  PubMed  Article  Google Scholar 

  50. 50

    Ogihara T, Sakai R, Fujita Y, et al: Pharmacokinetics of BIBR277 (telmisartan) in hypertensive patients with renal insufficiency. Jpn Pharmacol Ther 2002; 30 ( Suppl 1): 183–199.

    Google Scholar 

  51. 51

    Chew CG, Weise MD, Disney AP : The effect of angiotensin II receptor antagonist on the exogenous erythropoietin requirement of haemodialysis patients. Nephrol Dial Transplant 1999; 14: 2047–2049.

    CAS  PubMed  Article  Google Scholar 

  52. 52

    Kato A, Takita T, Furuhashi M, Takahashi T, Maruyama Y, Hishida A : No effect of losartan on response to erythropoietin therapy in patients undergoing hemodialysis. Nephron 2000; 86: 538–539.

    CAS  PubMed  Article  Google Scholar 

  53. 53

    Odabas AR, Cetinkaya R, Selcuk Y, Keles S, Bilen H : The effect of high dose losartan on erythropoietin resistance in patients undergoing haemodialysis. Panminerva Med 2003; 45: 59–62.

    CAS  PubMed  Google Scholar 

  54. 54

    Schwarzbeck A, Wittenmeier KW, Hallfritzsch U : Anaemia in dialysis patients as a side-effect of sartanes. Lancet 1998; 352: 286.

    CAS  PubMed  Article  Google Scholar 

  55. 55

    Sandle GI, Gaiger E, Tapster S, Goodship TH : Evidence for large intestinal control of potassium homoeostasis in uraemic patients undergoing long-term dialysis. Clin Sci (Lond) 1987; 73: 247–252.

    CAS  Article  Google Scholar 

  56. 56

    Hatch M, Freel RW, Vaziri ND : Local upregulation of colonic angiotensin II receptors enhances potassium excretion in chronic renal failure. Am J Physiol 1998; 274: F275–F282.

    CAS  PubMed  Google Scholar 

  57. 57

    Knoll GA, Sahgal A, Nair RC, Graham J, van Walraven C, Burns KD : Renin-angiotensin system blockade and the risk of hyperkalemia in chronic hemodialysis patients. Am J Med 2002; 112: 110–114.

    CAS  PubMed  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Kenichiro Kitamura.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Shimada, H., Kitamura, K., Anraku, M. et al. Effect of Telmisartan on Ambulatory Blood Pressure Monitoring, Plasma Brain Natriuretic Peptide, and Oxidative Status of Serum Albumin in Hemodialysis Patients. Hypertens Res 28, 987–994 (2005). https://doi.org/10.1291/hypres.28.987

Download citation

Keywords

  • telmisartan
  • blood pressure
  • brain natriuretic peptide
  • oxidative stress
  • hemodialysis

Further reading

Search